Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis
Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis
复制标题
DOI：
10.1007/s10147-007-0670-1
复制
发表时间：
2007-08-01
影响因子：
3.3
通讯作者：
Kikuchi, Yoshihiro
中科院分区：
文献类型：
--
作者：
Takano, Masashi;Sugiyama, Toru;Kikuchi, Yoshihiro
背景盐酸伊立替康是一种拓扑异构酶I抑制剂，已被初步认为是治疗卵巢透明细胞癌（CCC）的有效药物，但临床资料较少。我们的目的是比较盐酸伊立替康和顺铂（CPT-P）治疗患者与紫杉醇和卡铂（TC）治疗患者的无进展生存期（PFS）。通过扫描10家日本医院的病历，确定了117名国际妇产科联合会（FIGO）Ic期（腹水/恶性冲洗）- IV期患者。在完成包括淋巴结切除术在内的手术分期后，35例患者接受了CPT-P，82例患者接受了TC。采用Kaplan-Meier法比较两组患者的PFS和总生存期。CPT-P组和TC组之间的中位年龄、体能状态、FIGO分期、最佳细胞减灭率或随访时间无显著差异。TC组2年和5年PFS分别为48%和40%，CPT-P组分别为55%和55%（P = 0.31）。多因素回归分析显示，肿瘤残留是影响无进展生存的独立预后因素（P < 0.01）。CPT-P显示出潜在的治疗效果，至少不低于TC治疗。尽管在目前的回顾性分析中没有显着的生存益处，但我们建议在更大规模的前瞻性临床试验中评估CPT-P方案。
Background Irinotecan hydrochloride, a topoisomerase I inhibitor, has been preliminarily recognized as an effective agent against clear cell carcinoma of the ovary (CCC), but there are few clinical data. Our aim was to compare progression-free survival (PFS) between patients treated with irinotecan hydrochloride and cisplatin (CPT-P) and those with treated with paclitaxel and carboplatin (TC).Methods. One hundred and seventeen patients at International Federation of Gynecology and Obstetrics (FIGO) stages Ic (ascites/malignant washing) - IV were identified by scanning the medical records of ten Japanese hospitals. After complete surgical staging procedures including lymphadenectomy, 35 patients received CPT-P and 82 patients received TC. The PFS and overall survival of the two groups were compared using the Kaplan-Meier method.Results. There was no significant difference in median age, performance status, FIGO stage, rate of optimal cytoreduction, or follow-up period between the CPT-P and TC groups. Two-year and 5-year PFS was 48% and 40%, respectively, in the TC group and 55% and 55%, respectively, in the CPT-P group (P = 0.31). Multiple regression analysis revealed that only residual tumor was an independent prognostic factor for PFS (P < 0.01).Conclusion. CPT-P showed a potential therapeutic effect, at least no less than that of TC therapy. Although there was no significant survival benefit in the present retrospective analysis, we recommend that the CPT-P regimen be evaluated in a larger, prospective, clinical trial.